Expert Interview
Reviewing the results of Johnson & Johnson's SunRIse-1 trial for patients with Non-Muscle-Invasive Bladder Cancer
Ticker(s): JNJInstitution: Mayo Clinic
- Chairman, Department of Urology Research Committee & Chair, Mayo Clinic Cancer Center Local Genitourinary Disease Oriented Group (DOG).
- Currently manages over 1000 patients with prostate cancer & 50 patients each month with NMIBC.
- Research interests focus on recurrent and advanced urologic cancers, Bladder cancer: urine markers/treatment/surgery including reconstruction and replacement and Prostate cancer including nerve-sparing, testicular, penile, urethral cancers.
Describe your background and patient setting
Added By: ben_adminHow many patients with bladder cancer do you manage?
Added By: ben_adminWhat are your thoughts on the Sunrise-1 clinical data?
Added By: ben_adminWhere would TAR-200 or cetrelimab fit into your standard of care?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
